These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response. Marconato M; Abela IA; Hauser A; Schwarzmüller M; Katzensteiner R; Braun DL; Epp S; Audigé A; Weber J; Rusert P; Schindler E; Pasin C; West E; Böni J; Kufner V; Huber M; Zaheri M; Schmutz S; Frey BM; Kouyos RD; Günthard HF; Manz MG; Trkola A J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35482408 [TBL] [Abstract][Full Text] [Related]
26. SARS-CoV-2 neutralizing capacity among blood donors without prior COVID-19 symptomatic history vs. blood donors with prior COVID-19 symptomatic history: A comparative study. Ravula U; Chunchu SR; Mooli S; Naik R; Sarangapati PRR Transfus Clin Biol; 2022 May; 29(2):107-111. PubMed ID: 35167958 [TBL] [Abstract][Full Text] [Related]
27. Endemic Human Coronavirus Antibody Levels Are Unchanged after Convalescent or Control Plasma Transfusion for Early Outpatient COVID-19 Treatment. Karaba AH; Johnston TS; Beck E; Laeyendecker O; Cox AL; Klein SL; Sullivan DJ; mBio; 2023 Feb; 14(1):e0328722. PubMed ID: 36625657 [TBL] [Abstract][Full Text] [Related]
28. Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19. Sanz C; Nomdedeu M; Pereira A; Sauleda S; Alonso R; Bes M; Brillembourg H; García-Vidal C; Millan A; Martínez-Llonch N; Pirón M; Puerta-Alcalde P; Puig L; Rico V; Soriano A Transfusion; 2022 May; 62(5):974-981. PubMed ID: 35338710 [TBL] [Abstract][Full Text] [Related]
29. Surrogate test performance for SARS-CoV-2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): How useful could they be? Wendel S; Fachini R; Fontão-Wendel RCL; Mello R; Velasquez CV; Machado RRG; Brito MA; Amaral M; Soares CP; Achkar R; Scuracchio P; Miyaji SC; Erdens MS; Durigon EL Transfusion; 2021 Dec; 61(12):3455-3467. PubMed ID: 34674284 [TBL] [Abstract][Full Text] [Related]
30. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. Harvala H; Robb ML; Watkins N; Ijaz S; Dicks S; Patel M; Supasa P; Wanwisa D; Liu C; Mongkolsapaya J; Bown A; Bailey D; Vipond R; Grayson N; Temperton N; Gupta S; Ploeg RJ; Bolton J; Fyfe A; Gopal R; Simmonds P; Screaton G; Thompson C; Brooks T; Zambon M; Miflin G; Roberts DJ Transfus Med; 2021 Jun; 31(3):167-175. PubMed ID: 33333627 [TBL] [Abstract][Full Text] [Related]
31. Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients. Franchini M; Focosi D; Percivalle E; Beccaria M; Garuti M; Arar O; Pecoriello A; Spreafico F; Greco G; Bertacco S; Ghirardini M; Santini T; Schiavulli M; Stefania M; Gagliardo T; Sammartino JC; Ferrari A; Zani M; Ballotari A; Glingani C; Baldanti F Viruses; 2022 Jun; 14(7):. PubMed ID: 35891421 [TBL] [Abstract][Full Text] [Related]
32. Convalescent plasma in hospitalized pediatric and obstetric coronavirus disease 2019 (COVID-19) patients. Ikeda S; Benzi E; Hensch LA; Devaraj S; Hui SR; Gandhi M; Fox KA; Teruya J; Munoz FM Pediatr Int; 2022 Jan; 64(1):e15407. PubMed ID: 36326636 [TBL] [Abstract][Full Text] [Related]
33. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Bégin P; Callum J; Heddle NM; Cook R; Zeller MP; Tinmouth A; Fergusson DA; Cushing MM; Glesby MJ; Chassé M; Devine DV; Robitalle N; Bazin R; Shehata N; Finzi A; McGeer A; Scales DC; Schwartz L; Turgeon AF; Zarychanski R; Daneman N; Carl R; Amorim L; Gabe C; Ellis M; Sachais BS; Loftsgard KC; Jamula E; Carruthers J; Duncan J; Lucier K; Li N; Liu Y; Armali C; Kron A; Modi D; Auclair MC; Cerro S; Avram M; Arnold DM Trials; 2021 May; 22(1):323. PubMed ID: 33947446 [TBL] [Abstract][Full Text] [Related]
34. Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile. Sturek JM; Thomas TA; Gorham JD; Sheppard CA; Raymond AH; Petros De Guex K; Harrington WB; Barros AJ; Madden GR; Alkabab YM; Lu DY; Liu Q; Poulter MD; Mathers AJ; Thakur A; Schalk DL; Kubicka EM; Lum LG; Heysell SK Microbiol Spectr; 2022 Feb; 10(1):e0256021. PubMed ID: 35196802 [TBL] [Abstract][Full Text] [Related]
35. High-titer post-vaccine COVID-19 convalescent plasma for immunocompromised patients during the first omicron surge. Tayyar R; Wong LK; Dahlen A; Shu E; Pandey S; Liu AY Transpl Infect Dis; 2023 Apr; 25(2):e14055. PubMed ID: 36929619 [TBL] [Abstract][Full Text] [Related]
36. The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors. Kroemer M; Boullerot L; Ramseyer M; Spehner L; Barisien C; Gravelin E; Renaudin A; Cognasse F; Gallian P; Hermine O; Lacombe K; Tiberghien P; Adotévi O Front Public Health; 2022; 10():816848. PubMed ID: 35372242 [TBL] [Abstract][Full Text] [Related]